



# Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate

## OPEN ACCESS

### Edited by:

Daniele Zama,  
Sant'Orsola-Malpighi Polyclinic, Italy

### Reviewed by:

Yoichi Tanaka,  
Kitasato University, Japan  
Nathalie K. Zgheib,  
American University of  
Beirut, Lebanon  
Agnes F. Semsei,  
Semmelweis University, Hungary

### \*Correspondence:

Szymon Skoczen  
szymon.skoczen@uj.edu.pl

### Specialty section:

This article was submitted to  
Pediatric Hematology and  
Hematological Malignancies,  
a section of the journal  
Frontiers in Pediatrics

Received: 11 January 2020

Accepted: 13 May 2020

Published: 16 June 2020

### Citation:

Cwiklinska M, Czogala M, Kwiecinska K, Madetko-Talowska A, Szafarz M, Pawinska K, Wieczorek A, Klekawka T, Rej M, Stepień K, Halubiec P, Lazarczyk A, Miklusiak K, Bik-Multanowski M, Balwierz W and Skoczen S (2020) Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate. *Front. Pediatr.* 8:307. doi: 10.3389/fped.2020.00307

Magdalena Cwiklinska<sup>1,2</sup>, Malgorzata Czogala<sup>1,2</sup>, Kinga Kwiecinska<sup>1,2</sup>, Anna Madetko-Talowska<sup>3</sup>, Malgorzata Szafarz<sup>4</sup>, Katarzyna Pawinska<sup>1,2</sup>, Aleksandra Wieczorek<sup>1,2</sup>, Tomasz Klekawka<sup>1,2</sup>, Magdalena Rej<sup>1,2</sup>, Konrad Stepień<sup>1,2</sup>, Przemyslaw Halubiec<sup>5</sup>, Agnieszka Lazarczyk<sup>5</sup>, Karol Miklusiak<sup>5</sup>, Mirosław Bik-Multanowski<sup>3</sup>, Walentyna Balwierz<sup>1,2</sup> and Szymon Skoczen<sup>1,2\*</sup>

<sup>1</sup> Department of Oncology and Hematology, University Children's Hospital, Kraków, Poland, <sup>2</sup> Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Kraków, Poland, <sup>3</sup> Department of Medical Genetics, Chair of Pediatrics, Institute of Pediatrics, Jagiellonian University Medical College, Kraków, Poland, <sup>4</sup> Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland, <sup>5</sup> Student Scientific Group of Pediatric Oncology and Hematology, Jagiellonian University Medical College, Kraków, Poland

**Introduction:** High dose methotrexate (HD-Mtx) is highly effective and significantly improves overall acute lymphoblastic leukemia (ALL) patients survival. The pharmacodynamics of Mtx depends on the polymorphism of genes encoding proteins engaged in the folate metabolism pathway. The aim of the current study is to determine the relationship between variants of folate metabolism-related genes and the frequency of acute toxicities of HD-Mtx.

**Material and Methods:** A group of 133 patients aged 1.5–18.1 years (median: 6.3) was treated in accordance with the ALL-IC-2002 and ALL-IC-2009 protocols. The following polymorphisms were determined: 80 G>A *SLC19A1* (solute carrier family 19 member 1; rs1051266) with direct DNA sequencing, as well as 677 C>T *MTHFR* (methylenetetrahydrofolate reductase; rs1801133) and the tandem repeats of the *TS* (thymidylate synthase) with PCR technique. HD-Mtx organ toxicities were evaluated based on the laboratory tests results and the National Cancer Institute criteria.

**Results:** In patients with genotypes AA for *SLC19A1* and CC or CT for *MTHFR* Mtx steady state concentrations ( $C_{ss}$ ) and  $AUC_{inf}$  were distinctly higher. In patients with genotype 3R/3R for *TS* initial elimination rate constant was significantly higher ( $P = 0.003$ ). Patients receiving Mtx at the dose of 5 g/m<sup>2</sup> had lower clearance (4.35 vs. 8.92 L/h/m<sup>2</sup>) as compared to the ones receiving 2 g/m<sup>2</sup> that indicates non-linear Mtx elimination at the higher dose. Liver impairment was the most frequently observed

toxicity. The homozygous genotype was associated with a significantly higher incidence of hepatic toxicity for both the *SLC19A1* ( $P = 0.037$ ) and *TS* ( $P = 0.002$ ). Logistic regression analysis indicated an increased risk of vomiting for the 2R/3R genotype of the *TS* gene (OR 3.20, 95% CI 1.33–7.68,  $P = 0.009$ ) and for vomiting and hepatic toxicity for the 3R/3R genotype (vomiting: OR 3.39, 95% CI 1.12–10.23,  $P = 0.031$ ; liver toxicity: OR 2.28, 95% CI 1.05–4.95,  $P = 0.038$ ). None of the acute toxicities differed between the analyzed dosing groups.

**Conclusions:** Determination of polymorphisms of *SLC19A1*, *MTHFR*, and *TS* genes might allow for a better prior selection of patients with higher risk of elevated Mtx levels. Our study is the first one to report the increased risk of hepatotoxicity and vomiting in patients with *TS* polymorphisms.

**Keywords:** acute lymphoblastic leukemia, children, genes, polymorphism, methotrexate, pharmacokinetics, toxicity

## INTRODUCTION

Acute lymphoblastic leukemia (ALL) is diagnosed in about 30% of children with neoplastic diseases and is the most common neoplasm in pediatric population (1). Methotrexate (Mtx) is one of the key chemotherapeutic agents used in a high doses (HD) treatment regimens of childhood ALL. Due to the observed severe toxicity, HD-Mtx, defined as Mtx doses  $\geq 1$  g/m<sup>2</sup>, requires a proper monitoring of drug elimination and an adequate leucovorin rescue administration. Nonetheless, in some of ALL patients toxic plasma concentrations of Mtx are observed, causing severe acute chemotherapy complications. The resulting modifications of treatment regimens might negatively affect overall patient survival (2, 3).

To date, well-known risk factors of toxicity after prolonged Mtx exposition include drug-drug interactions, insufficient prehydration, older age, obesity or so called “third space fluid collections.” However, they do not explain all the changes observed in pharmacokinetics (PK) of Mtx in patients with childhood ALL. Numerous centers have performed comprehensive studies to explain the molecular basis of Mtx pharmacological activity and to identify genetic risk factors of its abnormal PK (3–6). As determined, Mtx enters the cell through the cell membrane by binding to the solute carrier family 19 member 1 (*SLC19A1*) (7–9). Inside the cell Mtx and its more active derivatives—polyglutamates block function of several enzymes of folate cycle, mainly dihydrofolate reductase (DHFR) responsible for production of active form of folate—tetrahydrofolate and thymidylate synthase (TS), involved in DNA synthesis (6, 10, 11). The final effect of Mtx pharmacological activity is blocking purine *de novo* synthesis and cells division. One of the main enzymes of the complex folate metabolism is methylenetetrahydrofolate reductase (MTHFR), that catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. Although Mtx does not directly inhibit MTHFR function, the activity of this enzyme is crucial for the body resources of tetrahydrofolate, that are necessary in DNA synthesis, as well as in methylation of DNA, lipids and proteins, including transformation of homocysteine into methionine. All

aspects of Mtx disposition and mechanism of action that we attempt to consider are summarized in **Figure 1**.


As has been shown previously *SLC19A1*, *TS* and *MTHFR* genes polymorphisms are common in the European population (12, 13). Different variants of these proteins can influence cytotoxic effect of Mtx and contribute to acute side effects of HD-Mtx therapy (12, 13). Although published, until now, results regarding relationship between polymorphisms of *SLC19A1*, *TS*, and *MTHFR* genes, increased Mtx plasma concentrations and intensive toxicities caused by HD-Mtx indicated importance of genetic polymorphisms, they have been sometimes conflicting (6, 8, 14–16). There are also studies showing a clear relationship between the polymorphisms of above-mentioned genes involved in folate metabolism with worse therapeutic prognosis for children with ALL (14, 17).

The aims of the current study were to assess the prevalence of *SLC19A1* 80 G>A and *MTHFR* 677 C>T genes polymorphisms as well as *TS* gene tandem repeats in the group of children treated due to ALL and its influence on Mtx pharmacokinetics and incidence of acute toxicities caused by HD-Mtx.

## MATERIALS AND METHODS

### Patients

The study group included 133 patients (**Table 1**), 1.5–18.1 years old (median: 6.3 years), treated in Department of Oncology and Hematology University Children’s Hospital in Krakow, Poland, in accordance with ALL-IC-2002 (132 patients) and ALL-IC-2009 (1 patient) protocols. Both protocols for SR and IR risk pre-B ALL as well as T-ALL patients had the same frame. They were composed of induction (prednisone, vincristine, daunorubicin, L-asparaginase, cyclophosphamide, arabinoside cytosine, 6-mercaptopurine, and intrathecal methotrexate); consolidation (high dose methotrexate, 6-mercaptopurine); reinduction (dexamethasone, vincristine, doxorubicin, L-asparaginase, cyclophosphamide, arabinoside cytosine, 6-thioguanine and intrathecal methotrexate) and maintenance therapy (6-mercaptopurine, low dose methotrexate, and intrathecal methotrexate). The consolidation Mtx dose in

**TABLE 1 |** Characteristic of patients according to Mtx dose.

Mtx dose g/m <sup>2</sup>	Patients nb.	Chemotherapy cycles (%)	Age (median) (4.9)	Gender (%)	BSA (%)	Type of ALL	Risk group	Cycles with delayed Mtx elimination (%)
2	123	478 (91%)	1.7–16.2 (4.9)	64 girls (52) 59 boys (48)	75: N (61) 29: > 75p. (23.6) 19: <3 p. (15.4)	121–pre B 2–pre T	SR 58.5% IR 41.5%	69 (14.4)
5	13	47 (9%)	1.5–18.1 (7.3)	2 girl (15.4) 11 boys (84.6)	9: N (69.2) 3: >75 p. (23.1) 1: < 3 p. (7.7)	1–pre B 12–pre T	IR 100%	28 (59.6)

p., percentyl.

ALL-IC-2002 was 2 g/m<sup>2</sup> for all children with precursor-B, standard and intermediate risk ALL group. For T-ALL the dose was 5 g/m<sup>2</sup>. In ALL-IC-2009 the IR group and T-ALL were treated with Mtx at the dose of 5 g/m<sup>2</sup>, SR patients had the same dose of 2 g/m<sup>2</sup>. In both protocols the only additional drug given simultaneously was 6-mercaptopurine at the dose of 25 mg/m<sup>2</sup>. Together, 525 Mtx-chemotherapy cycles given in consolidation phase (protocol M) were studied. Two patients were given 1 cycle at the Mtx dose of 2 g/m<sup>2</sup>, and 3 cycles at the dose of 5 g/m<sup>2</sup>. One

patient was given 3 cycles at the Mtx dose of 2 g/m<sup>2</sup>, and 1 cycle at the dose of 5 g/m<sup>2</sup> (Table 1).

## Genetic Analysis

Genetic analysis was performed in the laboratory with the international QC certificates (EMQN). DNA for molecular analyses was extracted with standard methods from blood mononuclears (0.5 ml of blood was collected from every patient; QIAamp DNA Blood Mini Kit was used, manufactured by

QIAGEN). Assessment of 80 G>A *SLC19A1* polymorphism was performed with direct DNA sequencing (Sanger's method). In turn, 677C>T *MTHFR* polymorphism was analyzed with PCR-RFLP technique and *TS* tandem repeats were assessed based on the PCR with subsequent agarose gel electrophoresis (12). Based on genotyping results the patients were divided into 3 groups ("wild" genotype, heterozygotes, homozygotes). The sequences of primers that were used for genotyping were presented in the **Supplementary Material**.

## Pharmacokinetic Analysis

Pharmacokinetic parameters of Mtx were calculated based on the routinely measured concentrations after the HD-Mtx administration. The blood samples were taken at the end of 24 h infusion (steady state) and in the elimination phase at 36, 42, and 48 h from the beginning of the Mtx administration (i.e., 12, 18, and 24 h after the end of infusion). In the cases where the last concentration measured was above 0.4  $\mu\text{M}$  (indication of prolonged Mtx elimination) subsequent samples were taken at the selected time points until the Mtx level decreased below 0.25  $\mu\text{M}$ . Because of the potential for capacity-limited intracellular transport and renal clearance the elimination of Mtx is not accurately described by linear pharmacokinetic model. However, relatively simple two-compartment model appears to represent quite well the elimination phase. Therefore, the elimination constants ( $k_{el}$ ) for both initial  $\alpha$  (up to 12 h after the end of infusion) and terminal  $\beta$  (from 12 to 24 h after the end of infusion) phases were calculated by log-linear regression of the drug concentration data in the appropriate phase. The area under the concentration vs. time curve extrapolated to infinity ( $\text{AUC}_{inf}$ ) was estimated using the log-linear trapezoidal rule and the total clearance (normalized per  $\text{m}^2$  of BSA) was calculated from  $\text{dose}/\text{AUC}_{inf}$ . Mtx concentrations were analyzed with immunoenzymatic method on the VIVA-Vitalab analyzer, DADE-BEHRING, USA.

## Pharmacodynamic Analysis

The pharmacodynamics study was concentrated on the analysis of acute toxicity observed during the chemotherapy cycles at the Mtx doses of 2 and 5  $\text{g}/\text{m}^2$ . Every cycle, independent of HD-Mtx dose, was administered to a patient in good clinical condition, after exclusion of acute infection and with normal renal and liver functions. The routine blood tests panel included complete blood count, blood urea nitrogen, creatinine, total protein, albumin, bilirubin, alanine transaminase, aspartate transaminase, and electrolytes (all tests were measured in SI units). Tests were performed 1 day before HD-Mtx administration and 48 h after starting the infusion (24 h after the end of infusion). HD-Mtx toxicity was evaluated based on the analysis of laboratory tests results and clinical features according to the National Cancer Institute criteria (NCI 3.0 version). Liver (SGOT/SGPT, bilirubin), blood/bone marrow (WBC, PLT, Hgb, ANC) and gastrointestinal (vomiting, stomatitis) toxicities as well as concomitant infections were studied. Grades  $\geq 2$  according to NCI criteria were analyzed. Liver function was considered to be impaired if the following criteria (based on our own experience) were met: increase in transaminases level at least 1 grade and/or

bilirubin grade  $\geq 2$  and/or decrease in protein level at least 13% comparing to the values observed before the actual cycle. Data concerning toxicity were collected prospectively at each cycle of chemotherapy, and were the basis for the subsequent therapeutic decisions, than all patients charts were reviewed.

## Statistical Analysis

Statistical analyses were performed with Statistica 12.0 (StatSoft, Statistica 12.0, Tulsa, Oklahoma, USA) software. Chi-square, Pearson chi-square and Fisher exact tests were used to identify relations between categorical variables. Comparison of numerical variables was performed using one-way ANOVA with *post-hoc* Tukey test or non-parametric Kruskal-Wallis test depending on the sample size. Allelic separation consistency within observed group of patients with expected allele distribution according to Hardy-Weinberg's rule was checked with use of the Chi-square test. Multiple logistic regression analysis was performed to identify risk factors of increased HD-Mtx therapy toxicities. Bonferroni correction for multiple comparisons was applied when assessing associations of toxicities and genetic variants, separately for each gene assessed. P-value of  $<0.05$  was considered statistically significant.

## RESULTS

The distribution of observed genotypes was consistent with the Hardy-Weinberg equilibrium (**Table 2**).

### Pharmacokinetic Results

As expected, steady state concentrations of Mtx in patients treated with 5  $\text{g}/\text{m}^2$  were significantly higher than in those receiving 2  $\text{g}/\text{m}^2$  (137 vs. 38.5  $\mu\text{M}$ ). Moreover, the overall mean  $\text{AUC}_{inf}$  values were higher than proportionally expected (2,510  $\mu\text{M}\cdot\text{h}$  for 5  $\text{g}/\text{m}^2$  vs. 717  $\mu\text{M}\cdot\text{h}$  for 2  $\text{g}/\text{m}^2$ ) indicating lower total clearance in patients receiving Mtx at the dose of 5  $\text{g}/\text{m}^2$  as compared to the ones receiving 2  $\text{g}/\text{m}^2$  (4.35 vs. 8.92  $\text{L}/\text{h}/\text{m}^2$ , respectively). Furthermore, the percentage of patients with prolonged elimination, defined as the concentration  $> 0.4 \mu\text{M}$  at 48 h after the beginning of infusion, was much higher in the group receiving Mtx at the dose of 5  $\text{g}/\text{m}^2$  (59.6 vs. 14.4%) (**Table 1**). These data might indicate that at the higher dose Mtx elimination process approaches saturation resulting in non-linearity of PK (**Tables 3, 4**). The possible variations in the Mtx levels resulting from non-linear elimination could influence the statistical analysis of the relationship between the genetic polymorphism and Mtx PK parameters. Moreover, due to limited number of observations, in the group receiving Mtx at the dose of 5  $\text{g}/\text{m}^2$  the non-parametric statistical tests were used which are less powerful. Therefore, analysis of the influence of genetic polymorphism on PK of Mtx was mostly based on the parameters calculated after the dose of 2  $\text{g}/\text{m}^2$ . All the obtained results are presented in **Tables 3, 4** as well as in **Figure 2** (multiple comparison). Mean steady state concentrations of Mtx were significantly higher (42.9 vs. 36.9 or 37.3  $\mu\text{M}$ ) in homozygotes AA of 80 G>A gene *SLC19A1* polymorphism ( $P = 0.0467$ ). Also homozygotes CC and heterozygotes 677 C>T of *MTHFR* gene had significantly higher (41.3 or 37.3

**TABLE 2** | The distribution of observed genotypes.

Gene	Variant 1	Variant 2	Variant 3	Consistent with the Hardy-Weinberg
80 G>A gene <i>SLC19A1</i>	GG—45 patients (33.8%)	AG—50 patients (37.6%)	AA—38 patients (28.6%)	( $P = 0.054$ , $\chi^2 = 5.84$ , $df = 2$ )
677 C>T gene <i>MTHFR</i>	CC—66 patients (49.6%)	CT—54 patients (40.6%)	TT—13 patients (9.8%)	( $P = 0.89$ , $\chi^2 = 0.22$ , $df = 2$ )
TS gene tandem repeats	2R/2R—29 patients (21.8%)	2R/3R—76 patients (57.1%)	3R/3R—28 patients (21.1%)	( $P = 0.37$ , $\chi^2 = 1.99$ , $df = 2$ )

**TABLE 3** | Methotrexate (Mtx) steady-state concentrations and basic pharmacokinetic parameters, calculated after administration of Mtx at the dose of 2 g/m<sup>2</sup>, depending on the observed genotype.

	Total (n = 478)	GG (n = 175)	GA (n = 180)	AA (n = 123)	P value
<b><i>SLC19A1</i> gene</b>					
Prolonged elimination	69 (14.4%)	26 (14.9%)	31 (17.2%)	12 (9.8%)	NS
C <sub>SS</sub> [μM]	38.5 (36.5–40.5)	36.9 (33.6–40.1)	37.3 (34.4–40.2)	42.9 (38.3–47.6)	0.0467
k <sub>el</sub> alfa [1/h]	0.30 (0.29–0.30)	0.29 (0.28–0.30)	0.29 (0.28–0.30)	0.31 (0.31–0.32)	0.0007
AUC <sub>inf</sub> [μM·h]	717 (680–755)	690 (630–740)	696 (640–751)	797 (712–883)	0.0566
CL [L/h/m <sup>2</sup> ]	8.92 (7.96–9.88)	9.51 (8.06–10.97)	9.25 (7.22–11.3)	7.40 (6.55–8.25)	NS
	Total (n = 478)	CC (n = 246)	CT (n = 184)	TT (n = 48)	P value
<b><i>MTHFR</i> gene</b>					
Prolonged elimination	69 (14.4%)	37 (15.0%)	25 (13.6%)	7 (14.6%)	NS
C <sub>SS</sub> [μM]	38.5 (36.5–40.5)	41.3 (38.3–44.3)	37.3 (34.3–40.3)	28.4 (24.4–32.9)	0.0007
k <sub>el</sub> alfa [1/h]	0.30 (0.29–0.30)	0.30 (0.29–0.31)	0.30 (0.29–0.31)	0.28 (0.26–0.30)	0.0465
AUC <sub>inf</sub> [μM·h]	717 (680–755)	770 (714–826)	694 (639–750)	531 (452–611)	0.0073
CL [L/h/m <sup>2</sup> ]	8.92 (7.96–9.88)	8.42 (6.9–9.9)	8.66 (7.71–9.61)	12.50 (8.10–16.91)	0.0496
	Total (n = 478)	2R2R (n = 100)	3R2R (n = 283)	3R3R (n = 95)	P value
<b><i>TS</i> gene</b>					
Prolonged elimination	69 (14.4%)	12 (12.0%)	43 (15.2%)	14 (14.7%)	NS
C <sub>SS</sub> [μM]	38.5 (36.5–40.5)	35.9 (31.1–40.7)	37.9 (35.5–40.3)	42.9 (37.9–47.7)	NS
k <sub>el</sub> alfa [1/h]	0.30 (0.29–0.30)	0.28 (0.27–0.30)	0.30 (0.29–0.30)	0.31 (0.30–0.32)	0.0034
AUC <sub>inf</sub> [μM·h]	717 (680–755)	680 (589–771)	705 (661–751)	792 (702–881)	NS
CL [L/h/m <sup>2</sup> ]	8.92 (7.96–9.88)	10.29 (7.88–12.70)	8.96 (7.62–10.3)	7.35 (6.31–8.38)	NS

Values are given as mean and 95 CI. Comparisons were performed using one-way ANOVA. The number of patients with prolonged elimination (Mtx concentration measured at 48 h from the beginning of the infusion  $\geq 0.4 \mu\text{M}$ ) is given in both unrelative (N) and relative (%) way. Pearson chi-square was used to identify relations between prolonged Mtx elimination and genotype. C<sub>SS</sub>, steady state concentration; k<sub>el</sub> alfa, initial elimination rate constant; AUC<sub>inf</sub>, area under the concentration-time curve extrapolated to infinity; CL, clearance; NS, non significant.

vs. 28.4 μM) mean Mtx steady state plasma concentrations in comparison to TT homozygotes ( $P = 0.0007$ ). In the case of TS gene polymorphism slightly higher (42.9 vs. 35.9 or 37.9 μM) concentrations were observed for homozygotes 3R/3R for tandem repeats of the TS gene however the difference did not reach statistical significance. In the patients receiving Mtx at the dose of 2 g/m<sup>2</sup> initial elimination rate constant and AUC<sub>inf</sub> were significantly lower ( $P = 0.0465$  and  $P = 0.00073$ , respectively) in homozygotes TT C>T of *MTHFR* gene, thus indicating higher clearance (12.5 vs. 8.42 L/h/m<sup>2</sup> in e.g., homozygotes CC). Furthermore, the significant correlation has been found between initial elimination rate constant and polymorphism of *SLC19A1* and TS genes. Elimination rate constant was significantly higher in homozygotes 3R/3R for tandem repeats of the TS gene ( $P$

$= 0.00343$ ) and in homozygotes AA of 80 G>A gene *SLC19A1* ( $P = 0.0007$ ), however in the latter case the AUC<sub>inf</sub> was also higher ( $P = 0.05$ ). On the contrary, for the dose of 5 g/m<sup>2</sup> in homozygotes AA of 80 G>A gene *SLC19A1* initial elimination rate constant was significantly lower (GG vs. AA  $P = 0.0319$ ) (Figure 2C). There was no significant influence of studied genetic polymorphism on the terminal elimination rate constant, although this is not a surprise since most of Mtx is eliminated during the  $\alpha$  phase.

## Pharmacodynamic Results

In the case of homozygotes AA (80 G>A gene *SLC19A1* polymorphism), a statistical trend for higher incidence of transaminase elevation was observed ( $P = 0.037$  without

**TABLE 4 |** Methotrexate (Mtx) steady-state concentrations and basic pharmacokinetic parameters, calculated after administration of Mtx at the dose of 5 g/m<sup>2</sup>, depending on the observed genotype.

	Total (n = 47)	GG (n = 4)	GA (n = 20)	AA (n = 23)	P value
<b>SLC19A1 gene</b>					
Prolonged elimination	28 (59.6%)	1 (25.0%)	14 (70.0%)	13 (56.5%)	NS
C <sub>SS</sub> [μM]	137 (24–230)	185 (139–230)	147 (42–200)	76 (24–200)	0.0015
k <sub>el</sub> alfa [1/h]	0.33 (0.18–0.46)	0.43 (0.35–0.46)	0.34 (0.21–0.41)	0.32 (0.18–0.39)	0.0345
AUC <sub>inf</sub> [μM·h]	2510 (446–5467)	3617 (2527–4216)	2718 (776–3645)	1392 (446–5467)	0.0019
CL [L/h/m <sup>2</sup> ]	4.35 (0.80–24.6)	3.11 (2.61–4.35)	4.05 (3.02–14.17)	6.66 (0.8–24.6)	0.0295
	Total (n = 47)	CC (n = 13)	CT (n = 30)	TT (n = 4)	P value
<b>MTHFR gene</b>					
Prolonged elimination	28 (59.6%)	11 (84.6%)	15 (50.0%)	2 (50.0%)	NS
C <sub>SS</sub> [μM]	137 (24–230)	140 (24–197)	138 (35–230)	109 (89–146)	NS
k <sub>el</sub> alfa [1/h]	0.33 (0.18–0.46)	0.34 (0.27–0.37)	0.33 (0.18–0.46)	0.34 (0.21–0.36)	NS
AUC <sub>inf</sub> [μM·h]	2510 (446–5467)	2551 (446–3603)	2519 (680–5467)	1985 (1626–2727)	NS
CL [L/h/m <sup>2</sup> ]	4.35 (0.80–24.6)	4.31 (3.0–24.6)	4.28 (0.8–16)	5.55 (4.0–6.8)	NS
	Total (n = 47)	2R2R (n = 16)	3R2R (n = 19)	3R3R (n = 12)	P value
<b>TS gene</b>					
Prolonged elimination	28 (59.6%)	7(43.8%)	13 (68.4%)	8 (66.7%)	NS
C <sub>SS</sub> [μM]	137 (24–230)	109 (24–200)	145 (44–230)	122 (35–195)	NS
k <sub>el</sub> alfa [1/h]	0.33 (0.18–0.46)	0.34 (0.21–0.37)	0.33 (0.18–0.46)	0.32 (0.18–0.41)	NS
AUC <sub>inf</sub> [μM·h]	2510 (446–5467)	1985 (446–3645)	2645 (861–5467)	2229 (680–3533)	NS
CL [L/h/m <sup>2</sup> ]	4.35 (0.80–24.6)	5.55 (3.0–24.6)	3.89 (0.8–12.8)	5.0 (1.29–14.2)	NS

Values are given as median and range. Comparisons were performed using Kruskal-Wallis test (small samples size). The number of patients with prolonged elimination (Mtx concentration measured at 48 h from the beginning of the infusion  $\geq 0.4 \mu\text{M}$ ) is given in both unrelative (N) and relative (%N) way. Pearson chi-square was used to identify relations between prolonged Mtx elimination and genotype. C<sub>SS</sub>, steady state concentration; k<sub>el</sub> alfa, initial elimination rate constant; AUC<sub>inf</sub>, area under the concentration-time curve extrapolated to infinity; CL, clearance; NS, non significant.

correction for multiple comparisons). Furthermore, similar trend was observed in the case of 3R/3R genotype of *TS* tandem repeats ( $P = 0.002$  without correction for multiple comparisons or 0.01 with Bonferroni correction). No significant influence of all analyzed polymorphisms on the incidence of hematological toxicity, vomiting, gastrointestinal mucositis, and infections was observed (Table 5).


Occurrences of particular acute toxicities induced by HD-Mtx were also analyzed with logistic regression models (Table 6). All commonly known risk factors of acute adverse reactions to HD-Mtx, such as: dose, prolonged drug exposure, age, as well as genotype were included. Heterozygous genotype 2R/3R of *TS* tandem repeats was associated with significant increase in stated intensive vomiting (OR adjusted to the wild-type genotype 3.20, 95% CI 1.33–7.68;  $P = 0.009$ ). Similar relationship was also observed in the case of 3R/3R homozygotes (adjusted OR 3.39, 95% CI 1.12–10.23;  $P = 0.031$ ). Additionally, as also demonstrated by logistic regression, 3R/3R polymorphism was associated with a higher risk of hepatotoxicity (adjusted OR 2.28, 95% CI 1.05–4.95;  $P = 0.038$ ). No such relationships were observed for the other analyzed polymorphisms as well as for other acute toxicities.

## Impact of Particular Mtx Dosage (2 vs. 5 g/m<sup>2</sup>) on Toxicity

In this study, 525 chemotherapy cycles with 2 and 5 g/m<sup>2</sup> Mtx doses (478 and 47 cycles, respectively) were analyzed. Impaired liver function, the most common acute toxicity, was observed with the same frequency in both groups. For the dosing of 2 and 5 g/m<sup>2</sup> it was 68.4 and 66.7% of all patients, respectively ( $P = 0.816$ ). Surprisingly, none of the acute toxicities differed between the analyzed groups (Table 7). Only an insignificant relationship was observed toward a higher incidence of hematological toxicity in the group treated with higher doses of Mtx (12.3 vs. 22.9%,  $P = 0.124$ ) (Table 7). In all patients adequate antitoxic therapy according to the requirements of protocols prevented life-threatening complications.

## DISCUSSION

We showed in our study that the genetic polymorphisms of the *SLC19A1*, *MTHFR*, and *TS* genes can influence pharmacokinetics of Mtx. Importantly, we have observed, for the first time in the literature, the increased risk of hepatotoxicity (significant



**FIGURE 2 |** Results of analysis of influence of genetic polymorphisms on elimination of Mtx in both dosing groups: **(A)** Relationship between the initial elimination rate constant ( $k_{el}$  alpha) and SLC19A1 gene polymorphism in the patients receiving Mtx at the dose of 2 g/m<sup>2</sup>. Values are presented as mean and 95CI. **(B)** Relationship between the area under the concentration-time curve extrapolated to infinity (AUC<sub>inf</sub>) and SLC19A1 gene polymorphism in the patients receiving Mtx at the dose of 2 g/m<sup>2</sup>. Values are presented as mean and 95CI. **(C)** Relationship between the initial elimination rate constant ( $k_{el}$  alpha) and SLC19A1 gene polymorphism in the patients receiving Mtx at the dose of 5 g/m<sup>2</sup>. Values are presented as median and range. **(D)** Relationship between the initial elimination rate constant ( $k_{el}$  alpha) and TS gene polymorphism in the patients receiving Mtx at the dose of 2 g/m<sup>2</sup>. Values are presented as mean and 95CI. **(E)** Relationship between the area under the concentration-time curve extrapolated to infinity (AUC<sub>inf</sub>) and MTHFR gene polymorphism in the patients receiving Mtx at the dose of 2 g/m<sup>2</sup> Values are presented as mean and 95CI. **(F)** Relationship between the initial elimination rate constant ( $k_{el}$  alpha) and MTHFR gene polymorphism in the patients receiving Mtx at the dose of 2 g/m<sup>2</sup>. Values are presented as mean and 95CI.

**TABLE 5** | Statistical significance (\*Bonferroni correction for multiple comparisons) of particular acute toxicities depending on the three analyzed genes polymorphisms.

Type of toxicity	AA <i>SLC19A1</i> , P value	N (%)	TT <i>MTHFR</i> , P value	N (%)	3R/3R <i>TS</i> , P value	N (%)
Features of impaired liver function	0.037 (*NS)	110 (75.3)	0.609 (*NS)	38 (73.1)	0.002 (*0.01)	83 (76.9)
Hematological toxicity	0.657 (*NS)	17 (11.6)	0.248 (*NS)	5 (9.6)	0.453 (*NS)	18 (16.7)
Vomiting	0.056 (*NS)	19 (13.0)	0.682 (*NS)	7 (13.5)	0.102 (*NS)	15 (13.9)
Mucositis	0.590 (*NS)	10 (6.9)	0.341 (*NS)	2 (3.9)	0.207 (*NS)	14 (13.0)
Infections	0.056 (*NS)	12 (8.2)	0.424 (*NS)	6 (11.5)	0.560 (*NS)	7 (6.5)

NS, non significant.

**TABLE 6** | Logistic regression analysis of acute toxicities adjusted to prolonged exposure to methotrexate, drug dose, age, and genotype.

Polymorphism	Genotype	Hepatotoxicity	P value	Vomiting	P value
80 G>A <i>SLC19A1</i>	hom GG	1.00 (-)	-	1.00 (-)	-
	het GA	1.44 (0.81–2.55)	NS	0.40 (0.16–1.02)	0.054
	hom AA	1.87 (0.96–3.63)	0.066	0.85 (0.35–2.03)	NS
2R>3R <i>TS</i>	hom 2R/2R	1.00 (-)	-	1.00 (-)	-
	het 2R/3R	1.46 (0.78–2.73)	NS	3.20 (1.33–7.68)	0.009
	hom 3R/3R	2.28 (1.05–4.95)	0.038	3.39 (1.12–10.23)	0.031
677 C>T <i>MTHFR</i>	hom CC	1.00 (-)	-	1.00 (-)	-
	het CT	1.07 (0.63–1.81)	NS	0.83 (0.43–1.63)	NS
	hom TT	1.22 (0.65–2.29)	NS	1.34 (0.32–5.59)	NS

Data are shown as odds ratios with 95% confidence intervals.

NS, non significant.

**TABLE 7** | The incidence of chemotherapy toxicities depending on the methotrexate doses.

Toxicity	2 g/m <sup>2</sup> N (%)	5 g/m <sup>2</sup> N (%)	P value
Impaired liver function	327 (68.4)	32 (66.7)	NS
Vomiting	52 (10.9)	9 (18.8)	NS
Stomatitis/skin inflammation	42 (8.8)	4 (8.3)	NS
Infections	39 (8.2)	4 (8.3)	NS
Hematological toxicity	59 (12.3)	11 (22.9)	NS

NS, non significant.

even with Bonferroni correction) and vomiting in patients with particular *TS* polymorphism and for the second time the increased risk of hepatotoxicity in the *SLC19A1* homozygous genotype. Surprisingly, the Mtx dose did not affect the incidence of individual toxicities, which may indicate a congenital predisposition to their development in individual ALL patients.

## ***SLC19A1* 80 G>A Polymorphism and Its Influence on Hepatotoxicity**

*SLC19A1* 80 G>A is a common single nucleotide polymorphism among genes responsible for Mtx transport into a cell (6, 14, 17–20). Our results indicate a relationship between the AA genotype of the *SLC19A1* 80 G>A polymorphism and

significantly elevated steady state Mtx concentrations after HD-Mtx infusions (e.g., 42.9 vs. 36.9 μM) (Table 3). Since this particular mutation is responsible for the lower affinity of the transporter protein to Mtx, it is expected that in these patients the higher amount of drug stays in the central circulation. Although patients, with this genotype, receiving the lower dose of Mtx had higher initial elimination rate constant (e.g., 0.315 vs. 0.292 1/h for AA vs. GG;  $P = 0.0012$ ) (Figure 2A), the total clearance was lower (higher  $AUC_{inf}$ ; e.g., 798 vs. 690 μM·h for AA vs. GG) (Figure 2B). On the contrary patients with AA genotype of the *SLC19A1* receiving 5 g/m<sup>2</sup> of Mtx had significantly lower initial elimination rate constant (e.g., 0.323 vs. 0.431 1/h for AA vs. GG;  $P = 0.0319$ ) (Figure 2C). However, these changes are rather consequences of the saturation of Mtx elimination processes. Higher Mtx exposure in AA homozygotes might result in the impaired liver function, defined by us as increase in transaminases level at least 1 grade and/or bilirubin grade  $\geq 2$  and/or decrease protein level, that was observed significantly more frequently (not significant with Bonferroni correction) in these patients. Until now, only one study showed a correlation between the 80 AA variant and significant liver function impairment caused by Mtx. Moreover, it was referred only to the group of patients with an additional, specific variant of *GSTM1* gene (15). The mechanism explaining increased liver toxicity, despite the presence of a variant of reduced folate carrier (RFC) protein with lower ability to transport Mtx (also into hepatocytes), may involve the participation of other transporters, with higher expression in liver tissues. The explanation could

be the activity of OATP1A/1B which determine transport of drugs (including Mtx) into hepatocytes (21), alteration of the polyglutamylation pattern (22) or the intracellular level of miR-595 acting as a phenotypic regulator of Mtx sensitivity in cells by targeting *SLC19A1* (23) (**Figure 1**).

The association between *SLC19A1* polymorphism and Mtx levels, similar to the one observed in our study, was also shown by Laverdière et al. (9). Since then, several researchers have observed the impact of this polymorphism on incidence of specific adverse reactions. Kotnik et al. showed an association of AA genotype with leukopenia, while Gregers et al. with significant percentage of serious myelotoxicities (6, 24). In the study conducted by Salazar et al. the wild GG genotype was associated with thrombocytopenia and mucositis of grade at least 2 according to WHO (14). However, the opposite results were presented by some other researchers who did not find the impact of *SLC19A1* polymorphism on acute toxicities of HD-Mtx therapy, although liver toxicity was not investigated (3, 25–28).

It should be emphasized that the number of patients in our study almost 3-fold exceeds the total number of HD-Mtx treated patients reported in previous studies of Mtx hepatotoxicity. Thus, our results showing possible increased risk of HD-Mtx induced hepatotoxicity in patients with the *SLC19A1* 80 AA variant seem to be better substantiated. It should also be emphasized that previous studies were based on assessment of various ethnic groups and of patient cohorts of variable size. The polymorphisms of numerous genes involved in Mtx disposition might differ among various populations thus possibly determining the toxic effects of treatment (29).

## The Role of *TS* Repeats and Their Impact on Hepatotoxicity and Vomiting

The results of our study suggest that determination of the *TS* gene polymorphism in pediatric population may have significant clinical implications in predicting liver impairment associated with HD-Mtx (significant even with Bonferroni correction).

Mtx is an uncompetitive, irreversible inhibitor of *TS* and, from a pharmacokinetic point of view, this enzyme should have a relatively low contribution to Mtx elimination (30). However, slightly higher (without statistical significance) steady state Mtx concentrations were seen in homozygotes 3R/3R for tandem repeats of the *TS* gene (e.g., 42.9 vs. 35.9  $\mu\text{M}$  for 3R/3R vs. 2R/2R) (**Table 3**). Since simultaneous increase in the initial elimination rate has been also observed (e.g., 0.313 vs. 0.287 1/h for 3R/3R vs. 2R/2R;  $P = 0.0022$ ) (**Figure 2D**) the decrease in total clearance in the patients with 3R/3R variant for tandem repeats of the *TS* gene, although visible (7.35 vs. 10.29 L/h/m<sup>2</sup>), did not reach statistical significance (**Table 3**). The vast majority of Mtx is eliminated by renal route and the higher amount of proteins able to irreversibly bind Mtx might impair the elimination process, but this hypothesis needs further investigation. However, it should also be stressed that *TS* plays additional (not directly related to folate metabolism) role in cell homeostasis control through associations with numerous cell cycle proteins, in particular with p53. The mutual regulation of *TS* and p53 is based on negative feedback loop. In 3R/3R

cells with the higher *TS* expression the p53 level will be lower (31), what decreases ability of intensively dividing cells (e.g., hepatocytes and gastrointestinal epithelium cells) to block the cell cycle during exposure to the severely damaging factors acting during the S phase (such as Mtx). It may explain the increased incidence of mucosal and liver damage observed in our study (32). The published results regarding the influence of *TS* gene polymorphism on the incidence of different toxicities are not consistent. Ongaro et al. showed a significant increase in the risk of anemia in adult patients with 3R/3R genotype, while other researchers reported increased toxicity in the central nervous system (33–37). Opposite results were presented by Kotnik et al. and Erculj et al. showing that 3R/3R genotype was associated with a reduced risk of mucositis, leukopenia and thrombocytopenia (6, 38). Demonstrated by us relationship between 3R/3R genotype and increased hepatotoxicity, as we mentioned earlier, has not been reported previously.

## The Role of *MTHFR* 677 C>T Polymorphism in Toxicity of HD-Mtx

In our study, patients homozygotes CC and heterozygous for the common 677C>T polymorphism of the *MTHFR* gene achieved significantly higher steady state Mtx plasma concentrations (41.3 or 37.3 vs. 28.4  $\mu\text{M}$ ;  $P = 0.0007$ ) (**Table 3**). Elevated levels of Mtx in the carriers of CT variant of the *MTHFR* gene are consistent with several previous observations (16, 39, 40). However, we did not show significant differences in the frequency of acute side-effects of HD-Mtx in carriers of this polymorphism. Such results observed in our study could be partially explained by the fact that despite the higher steady state concentrations and higher AUC<sub>inf</sub> values (694 vs. 531  $\mu\text{M}\cdot\text{h}$  for CT vs. TT;  $P = 0.0373$ ) (**Figure 2E**) the carriers of this gene mutation had also slightly higher, although not significantly, initial elimination rate constant (0.3 vs. 0.28 1/h) (**Figure 2F**) indicating faster decrease of Mtx concentration immediately after the end of infusion. Lack of relationships between toxicity and *MTHFR* gene polymorphism have already been noticed by Seidemann et al. (41) and Shimasaki et al. (16), except for mucosal toxicity directly caused by higher drug plasma concentrations. However, other authors found higher frequency of mucosal toxicity or increased hematological toxicity associated with *MTHFR* gene polymorphism (29, 42, 43). El-Khodary et al. described increased hepatic and myeloid toxicity in *MTHFR* 677TT homozygotes (44). The presence of the 677T allele was also associated with a higher risk of thrombocytopenia (45), and an overall increase in toxicity, if in combination with the 1298AC variant (46). Considering the conflicting reports presented in the literature it is highly possible that, in the case of 677C>T *MTHFR* gene polymorphism some other concomitant factors are likely to affect toxicity of HD-Mtx treatment.

## Limitations of the Study

Our study has some limitations. First, the tested polymorphisms seem to be important for the Mtx disposition, but the influence of other genetic and biochemical factors should be also considered. The influence of combinations of specific alleles of several genes, including possible synergistic or antagonistic effects are possible.

Second, more advanced genetic methods, such as whole exome sequencing, could provide more information on other potential polymorphisms associated with Mtx toxicity (47, 48). Third, our study group was homogenous as far as ethnicity is concerned, so this makes the discussion focused solely on the central European population.

## CONCLUSIONS

The genetic polymorphisms has an unquestionable effect on pharmacokinetics and toxicity of Mtx. Determination of polymorphisms of *SLC19A1*, *MTHFR*, and *TS* genes allows for a better selection of patients with higher risk of elevated Mtx levels. According to our knowledge, our study is the first one to report the increased risk of hepatotoxicity and vomiting in patients with particular *TS* polymorphisms. In addition, we were able to confirm the previous data showing that the increased risk of hepatotoxicity has been associated with the *SLC19A1* homozygous genotype. Surprisingly, the administered Mtx dose did not affect the incidence of individual toxicities. Further research, considering also polymorphisms of other folate metabolism pathways and some mutual gene associations, including meta-analyses of the previous studies, is necessary for the final determination of the role of individual polymorphisms in the pharmacokinetics, pharmacological activity, and toxicity of Mtx. Such studies could lead to the pharmacogenetically improved, individualized dosing of Mtx, that in turn could compensate for its interindividual PK variations.

## DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

## REFERENCES

- Steliarova-Foucher E, Colombet M, Ries LAG, Dolya A, Bray F, Hesselting P, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. *Lancet Oncol.* (2017) 18:719–31. doi: 10.1016/S1470-2045(17)30186-9
- Kaapor G, Sinha R, Abedin S. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country. *Pediatr Blood Cancer.* (2012) 59:448–53. doi: 10.1002/pbc.24081
- Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. *Leukemia.* (2008) 22:1798–800. doi: 10.1038/leu.2008.66
- Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. *Nat Rev Cancer.* (2006) 6:117–29. doi: 10.1038/nrc1800
- Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Mörck A, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. *Blood.* (2013) 121:5145–53. doi: 10.1182/blood-2013-01-480335
- Kotnik BE, Grabnar I, Grabar PB, Dolžan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by local Permanent Ethical Committee for Clinical Studies (KBET/96/B/2008). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

## AUTHOR CONTRIBUTIONS

MCw, MCz, KK, AM-T, MB-M, WB, and SS contributed to the study concept and design. MCw, MCz, KK, AM-T, KP, AW, TK, and MR performed diagnostic tests and collected relevant clinical data. MCw, MCz, AM-T, MS, KS, PH, AL, and KM conducted statistical analysis. MCw, MCz, MS, KS, PH, AL, and KM wrote sections of the manuscript. MB-M, WB, and SS critically revised the article. All authors were responsible for the integrity and accuracy of the data and approved the submitted version.

## FUNDING

This work was supported by a grant from the Jagiellonian University Medical College (K/ZDS/002440).

## ACKNOWLEDGMENTS

We thank Kamil Fijorek, Ph.D., for assistance with statistical analysis.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fped.2020.00307/full#supplementary-material>

- pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. *Eur J Clin Pharmacol.* (2011) 67:993–1006. doi: 10.1007/s00228-011-1046-z
- Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Söderhäll S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. *Leukemia.* (2009) 24:345–54. doi: 10.1038/leu.2009.251
- De Jonge R, Hooijberg JH, van Zelst BD, Jansen G, van Zantwijk CH, Kaspers GJL, et al. Effects of polymorphisms in folate-related genes on *in vitro* methotrexate sensitivity in pediatric acute lymphoblastic leukemia. *Blood.* (2005) 106:717–20. doi: 10.1182/blood-2004-12-4941
- Laverdière C, Chiasson S, Costea I, Moghrabi A, Krajcinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. *Blood.* (2002) 100:3832–4. doi: 10.1182/blood.V100.10.3832
- Krajcinovic M, Moghrabi A. Pharmacogenetics of methotrexate. *Pharmacogenomics.* (2004) 5:819–34. doi: 10.1517/14622416.5.7.819
- Panetta JC, Sparreboom A, Pui C-H, Relling MV, Evans WE. Modeling mechanisms of *in vivo* variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. *PLoS Comput Biol.* (2010) 6:1–13. doi: 10.1371/journal.pcbi.1001019
- Pietrzyk JJ, Bik-Multanowski M, Balwierz W, Skoczen S, Wojcik D, Chybicka A, et al. Additional genetic risk factor for death in children with acute

- lymphoblastic leukemia: a common polymorphism of the MTHFR gene. *Pediatric Blood Cancer*. (2009) 52:364–8. doi: 10.1002/pbc.21815
13. Pietrzyk JJ, Bik-Multanowski M, Skoczen S, Kowalczyk J, Balwierc W, Chybicka A, et al. Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. *Leuk Res*. (2011) 35:1464–6. doi: 10.1016/j.leukres.2011.04.007
  14. Salazar J, Altés A, Rives S, Estella J, Rives S, Tasso M, et al. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. *Pharmacogenomics J*. (2012) 12:379–88. doi: 10.1038/tpj.2011.25
  15. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. *J Hum Genet*. (2007) 52:166–71. doi: 10.1007/s10038-006-0096-z
  16. Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. *J Pediatr Hematol Oncol*. (2006) 28:64–8. doi: 10.1097/01.mph.0000198269.61948.90
  17. Ge Y, Haska CL, LaFiura K, Devidas M, Linda SB, Liu M, et al. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the children's oncology group. *Clin Cancer Res*. (2007) 13:451–7. doi: 10.1158/1078-0432.CCR-06-2145
  18. Yates Z, Luccock M. G80A reduced folate carrier SNP modulates cellular uptake of folate and affords protection against thrombosis via a non homocysteine related mechanism. *Life Sci*. (2005) 77:2735–42. doi: 10.1016/j.lfs.2005.02.029
  19. Chen Y, Shen Z. Gene polymorphisms in folate metabolism and their association with Mtx-related adverse events in the treatment of ALL. *Tumor Biol*. (2015) 36:4913–21. doi: 10.1007/s13277-015-3602-0
  20. Park JA, Shin HY. Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. *Blood Res*. (2016) 51:50–7. doi: 10.5045/br.2016.51.1.50
  21. van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. *Clin Cancer Res*. (2012) 19:821–32. doi: 10.1158/1078-0432.CCR-12-2080
  22. Sandhu A, Ahmad S, Kaur J, Bhatnagar A, Dhawan V, Dhir V. Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients. *Clin Rheumatol*. (2018) 37:3221–8. doi: 10.1007/s10067-018-4206-z
  23. Wang S-M, Sun L-L, Wu W-S, Yan D. MiR-595 suppresses the cellular uptake and cytotoxic effects of methotrexate by targeting SLC19A1 in CEM/C1 cells. *Basic Clin Pharmacol Toxicol*. (2018) 123:8–13. doi: 10.1111/bcpt.12966
  24. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthøj S, et al. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. *Blood*. (2010) 115:4671–7. doi: 10.1182/blood-2010-01-256958
  25. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Piñan MA, Garcia-Miguel P, Navajas A, et al. Polymorphisms of the SLC01B1 gene predict methotrexate-related toxicity in childhood lymphoblastic leukemia. *Pediatr Blood Cancer*. (2011) 57:612–19. doi: 10.1002/pbc.23074
  26. Rasmussen MM, Christensen RH, Gregers J, Heldrup J, Nersting J, Schmiegelow K. Can SLC19A1 80G>A polymorphisms predict risk of extremely delayed Mtx excretion after high dose of methotrexate? *Pediatr Hematol Oncol*. (2013) 35:417–18. doi: 10.1097/MPH.0b013e318290c11c
  27. Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Abboud MR, Solh H, et al. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in lebanese children with acute lymphoblastic leukemia. *Pharmacogenet Genom*. (2014) 24:387–96. doi: 10.1097/FPC.0000000000000069
  28. Suzuki R, Fukushima H, Noguchi E, Tsuchida M, Kiyokawa N, Koike K, et al. Influence of SLC01B1 polymorphism on maintenance therapy for childhood leukemia. *Pediatr Int*. (2015) 57:572–7. doi: 10.1111/ped.12682
  29. Zahra FT, Nahid NA, Islam MR, Al-Mamun MMA, Apu MNH, Nahar Z, et al. Pharmacogenetic variants in MTHFR gene are significant predictors of methotrexate toxicities in bangladeshi patients with acute lymphoblastic leukemia. *Clin Lymphoma Myeloma Leuk*. (2019) 20:e58–e65. doi: 10.1016/j.clml.2019.11.020
  30. Moran RG, Mulkins M, Heidelberger C. Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. *Proc Natl Acad Sci USA*. (1979) 76:5924–8. doi: 10.1073/pnas.76.11.5924
  31. Ju J, Pedersen-Lane J, Maley F, Chu E. Regulation of p53 expression by thymidylate synthase. *Proc Natl Acad Sci USA*. (1999) 96:3769–74. doi: 10.1073/pnas.96.7.3769
  32. Municio C, Soler Palacios B, Estrada-Capetillo L, Benguria A, Dopazo A, García-Lorenzo E, et al. Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis. *Ann Rheum Dis*. (2016) 75:2157–65. doi: 10.1136/annrheumdis-2015-208736
  33. Ongaro A, De Mattei M, Della Porta MG, Rigolin G, Ambrosio C, Di Raimondo F, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. *Haematologica*. (2009) 94:1391–8. doi: 10.3324/haematol.2009.008326
  34. Rocha JCC, Cheng C, Liu W, Kishi S, Das S, Cook EH, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. *Blood*. (2005) 105:4752–8. doi: 10.1182/blood-2004-11-4544
  35. Dulucq S, St-Onge G, Gagné V, Ansari M, Sinnott D, Labuda D, et al. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. *Blood*. (2008) 111:3692–700. doi: 10.1182/blood-2007-09-110593
  36. Krajcinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. *Lancet*. (2002) 359:1033–34. doi: 10.1016/S0140-6736(02)08065-0
  37. Krajcinovic M, Costea I, Primeau M, Dulucq S, Moghrabi A. Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. *Pharmacogenomics J*. (2005) 5:374–80. doi: 10.1038/sj.tpj.65.00332
  38. Erčulj N, Kotnik BF, Debeljak M, Jazbec J, Dolžan V. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. *Leuk Lymphoma*. (2012) 53:1096–104. doi: 10.3109/10428194.2011.639880
  39. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. *J Clin Oncol*. (2003) 21:3084–91. doi: 10.1200/JCO.2003.07.056
  40. Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Leuk Lymphoma*. (2009) 50:912–17. doi: 10.1080/10428190902893819
  41. Seidemann K, Book M, Zimmermann S, Meyer U, Welte K, Stanulla M, et al. MTHFR 677 (C→ T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. *Ann Hematol*. (2006) 85:291–300. doi: 10.1007/s00277-005-0072-2
  42. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. *Blood*. (2001) 98:231–4. doi: 10.1182/blood.V98.1.231
  43. D'Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M, et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. *Cancer Chemother Pharmacol*. (2011) 68:1339–46. doi: 10.1007/s00280-011-1665-1
  44. EL-Khodary NM, EL-Haggar SM, Eid MA, Ebeid EN. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. *Med Oncol*. (2011) 29:2053–62. doi: 10.1007/s12032-011-9997-6
  45. Liu S-G, Li Z-G, Cui L, Gao C, Li W-J, Zhao X-X. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. *Leuk Lymphoma*. (2011) 52:1030–40. doi: 10.3109/10428194.2011.563883
  46. Kałuzna E, Strauss E, Zajac-Spychała O, Gowin E, Swiatek-Kościelna B, Nowak J, et al. Functional variants of gene encoding folate

- metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia. *Eur J Pharmacol.* (2015) 769:93–9. doi: 10.1016/j.ejphar.2015.10.058
47. Skoczen S, Stepien K, Krzysztofik M, Luszawska T, Hnatko-Kolacz M, Korostynski M, et al. Genetic profile and clinical implications of hepatoblastoma and neuroblastoma coexistence in a child. *Front Oncol.* (2019) 9:230. doi: 10.3389/fonc.2019.00230
48. Skoczen S, Stepien K, Mlynarski W, Centkowski P, Kwiecinska K, Korostynski M, et al. Genetic signature of acute lymphoblastic leukemia and netherton syndrome co-incidence – first report in the literature. *Front Oncol.* (2019) 9:1477. doi: 10.3389/fonc.2019.01477

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Cwiklinska, Czogala, Kwiecinska, Madetko-Talowska, Szafarz, Pawinska, Wieczorek, Klekawka, Rej, Stepien, Halubiec, Lazarczyk, Miklusiak, Bik-Multanowski, Balwierz and Skoczen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.